Unity Biotechnology develops therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate, UBX1325, is in Phase II clinical trial for age-related eye diseases. The company also develops drugs for ophthalmologic diseases, age-related eye diseases, and multiple neurology indications. It was formerly known as Forge, Inc. and is headquartered in South San Francisco, California.